The PROGRESS Trial: A Prospective Randomized Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement

Brief description of study

This study is being done to see if the SAPIEN 3™ and SAPIEN 3 Ultra™ Transcatheter Heart Valve is beneficial for patients with moderate, calcific aortic stenosis. The SAPIEN 3™ and SAPIEN 3 Ultra™ Transcatheter Heart Valve are not approved by the Food and Drug Administration (FDA) for the treatment of moderate, calcific aortic stenosis and is considered experimental in this research.

Clinical Study Identifier: s21-01143 Identifier: NCT04889872
Principal Investigator: Richard K Schwartz.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.